Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. The Rybelsus® tablet brand demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Ozempic® injectable brand provides an additional indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM. In a recent development, semaglutide received FDA approval under the brand name Wegovy®, which is an injection used for promoting weight loss in individuals dealing with obesity and overweight. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.The numerous and evolving benefits of semaglutide are complicated due to differences in dosing and available preparations. Clinicians must obtain a firm grasp of how semaglutide may be used safely and effectively. This activity aims to provide a clear understanding of semaglutide, including its indications, benefits, mechanisms of action, potential adverse effects, monitoring recommendations, and general pharmacological characteristics. This activity also explores the essential role of the interprofessional healthcare team in improving patient outcomes with semaglutide.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/162828
- Start Date: 2024-12-01 06:00:00
- End Date: 2024-12-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABOS - 1.0 Point; Credit Type(s): Accredited CME (ABOS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Adult Cardiac, Advanced Heart Failure and Transplant Cardiology, Ambulatory/Outpatient, Bariatric Surgery, Cardiothoracic, Cardiovascular, Cardiovascular Disease, Chemical Pathology, Endocrinology, Diabetes, and Metabolism, General Operative Anesthesia, General Orthopaedics, General Pediatrics, General Surgery, Hospital Medicine, Internal Medicine, Medical Toxicology, Nephrology, Pediatric Cardiology, Pediatric Endocrinology, Pediatric Nephrology